Samsung Biologics America agreed to acquire Human Genome Sciences’ Rockville manufacturing facility from GSK for $280 million, a purchase that preserves more than 500 jobs and adds cGMP capacity to Samsung’s U.S. footprint. The site contains two drug‑substance plants totaling about 60,000 L and supports both clinical and commercial biologic production. Samsung said it will invest to expand and upgrade the facility to support next‑generation biologics, organoid services and diversified modalities. The acquisition supports reshoring and supply‑chain resilience trends as biopharma firms and contract manufacturers secure manufacturing capacity in the U.S. The deal strengthens Samsung Biologics’ global manufacturing network and positions the company to meet rising demand for biologics and advanced modalities from both domestic and international customers.